• Chunfang Xu, Jiaqing Shen, Jing Zhang, Zhenyu Jia, Zhilong He, Xiaohui Zhuang, Ting Xu, Yuqi Shi, Shunying Zhu, Mingyuan Wu, and Wei Han.
• Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
• Biochem. Pharmacol. 2015 Feb 15; 93 (4): 449-60.

AbstractChronic pancreatitis (CP) is a common disease in the department of gastroenterology, with the main symptoms of exocrine and/or endocrine insufficiency and abdominal pain. The pathogenic mechanism of CP is still not fully clarified and the aims of treatment now are to relieve symptoms. In this study, we attempted to find a connection between interleukin-1β (IL-1β) and interleukin-1 receptor antagonist (IL-1Ra) in trinitrobenzene sulfonic acid (TNBS)-induced chronic pancreatitis, and then the therapeutic effect of recombinant IL-1Ra was also detected in the CP model. Chronic pancreatitis was induced by intraductal infusion of TNBS in SD rats followed by a consecutive administration of rIL-1Ra, and the histological changes and collagen content in the pancreas were measured, as well as the abdominal hypersensitivity. We found that rhIL-1Ra could attenuate the severity of chronic pancreatic injury, modulate the extracellular matrix secretion, focal proliferation and apoptosis, and cellular immunity in TNBS-induced CP. Interestingly, rIL-1Ra could also block the pancreatitis-induced referred abdominal hypersensitivity. In conclusion, IL-1Ra may play a protective role in CP and rIL-1Ra would be a potential therapeutic target for the treatment of CP, while its possible mechanisms and clinical usage still need further investigation.Copyright © 2015 Elsevier Inc. All rights reserved.

20 keywords...

hide…